David Augustus Qualls, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Mantle-Cell | 3 | 2023 | 238 | 2.020 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 5 | 2025 | 1433 | 1.740 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2023 | 1372 | 0.830 |
Why?
|
| Superoxide Dismutase | 2 | 2013 | 596 | 0.730 |
Why?
|
| Antibodies, Bispecific | 1 | 2022 | 204 | 0.630 |
Why?
|
| Nephritis, Interstitial | 1 | 2019 | 157 | 0.610 |
Why?
|
| Lymphoma, Follicular | 1 | 2022 | 460 | 0.570 |
Why?
|
| Immunomodulation | 1 | 2019 | 548 | 0.490 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2025 | 11872 | 0.490 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2025 | 1502 | 0.490 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 9410 | 0.450 |
Why?
|
| Protein Folding | 2 | 2013 | 869 | 0.420 |
Why?
|
| Translocation, Genetic | 1 | 2018 | 1391 | 0.420 |
Why?
|
| Inclusion Bodies | 1 | 2013 | 277 | 0.400 |
Why?
|
| Methotrexate | 1 | 2018 | 1718 | 0.390 |
Why?
|
| Lymphoma | 1 | 2021 | 1896 | 0.390 |
Why?
|
| Mutant Proteins | 1 | 2013 | 487 | 0.390 |
Why?
|
| Spinal Injuries | 1 | 2015 | 300 | 0.380 |
Why?
|
| Luminescent Proteins | 1 | 2013 | 839 | 0.360 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2018 | 928 | 0.350 |
Why?
|
| Central Nervous System | 1 | 2017 | 1345 | 0.340 |
Why?
|
| Stem Cell Transplantation | 1 | 2017 | 1596 | 0.310 |
Why?
|
| Cervical Vertebrae | 1 | 2015 | 978 | 0.310 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2015 | 807 | 0.310 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 3599 | 0.270 |
Why?
|
| Graft Rejection | 1 | 2019 | 4498 | 0.260 |
Why?
|
| Cyclophosphamide | 2 | 2025 | 2227 | 0.250 |
Why?
|
| Heart Transplantation | 1 | 2019 | 3305 | 0.250 |
Why?
|
| Combined Modality Therapy | 3 | 2022 | 8535 | 0.240 |
Why?
|
| Brain Injuries | 1 | 2015 | 2053 | 0.210 |
Why?
|
| Positron-Emission Tomography | 1 | 2019 | 6550 | 0.210 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2013 | 1481 | 0.210 |
Why?
|
| Antineoplastic Agents | 2 | 2023 | 13650 | 0.210 |
Why?
|
| Antigens, CD19 | 2 | 2025 | 443 | 0.200 |
Why?
|
| CREB-Binding Protein | 1 | 2023 | 147 | 0.200 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2023 | 125 | 0.200 |
Why?
|
| Vincristine | 1 | 2025 | 1040 | 0.200 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2023 | 180 | 0.200 |
Why?
|
| Bacterial Proteins | 1 | 2013 | 3834 | 0.170 |
Why?
|
| Prednisone | 1 | 2025 | 1566 | 0.170 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2022 | 696 | 0.170 |
Why?
|
| Doxorubicin | 1 | 2025 | 2229 | 0.150 |
Why?
|
| Thiotepa | 1 | 2017 | 66 | 0.150 |
Why?
|
| Humans | 22 | 2025 | 767040 | 0.140 |
Why?
|
| Adenine | 1 | 2022 | 995 | 0.130 |
Why?
|
| Busulfan | 1 | 2017 | 259 | 0.130 |
Why?
|
| Quinazolines | 1 | 2022 | 1369 | 0.130 |
Why?
|
| Transplantation, Autologous | 2 | 2018 | 2118 | 0.130 |
Why?
|
| Biological Products | 1 | 2025 | 948 | 0.120 |
Why?
|
| Saponins | 1 | 2013 | 47 | 0.110 |
Why?
|
| Prognosis | 4 | 2023 | 29963 | 0.110 |
Why?
|
| Piperidines | 1 | 2022 | 1667 | 0.110 |
Why?
|
| Consensus | 1 | 2023 | 3207 | 0.110 |
Why?
|
| Glasgow Coma Scale | 1 | 2015 | 574 | 0.110 |
Why?
|
| Sarcopenia | 1 | 2018 | 378 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2018 | 20741 | 0.100 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2022 | 1076 | 0.100 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2022 | 2883 | 0.100 |
Why?
|
| Tumor Microenvironment | 2 | 2022 | 3944 | 0.100 |
Why?
|
| Remission Induction | 1 | 2017 | 2408 | 0.090 |
Why?
|
| Injury Severity Score | 1 | 2015 | 1049 | 0.090 |
Why?
|
| Antigens, CD | 1 | 2021 | 4032 | 0.090 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2019 | 2028 | 0.090 |
Why?
|
| Neoplasms | 1 | 2019 | 22350 | 0.090 |
Why?
|
| Pyrimidines | 1 | 2022 | 3044 | 0.090 |
Why?
|
| Retrospective Studies | 6 | 2025 | 81659 | 0.080 |
Why?
|
| Epigenesis, Genetic | 1 | 2023 | 3828 | 0.080 |
Why?
|
| Acute Disease | 1 | 2019 | 7236 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2025 | 8048 | 0.080 |
Why?
|
| Protein Multimerization | 1 | 2013 | 961 | 0.080 |
Why?
|
| Comorbidity | 1 | 2023 | 10582 | 0.080 |
Why?
|
| Graft Survival | 1 | 2019 | 3896 | 0.080 |
Why?
|
| Body Composition | 1 | 2018 | 2454 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2025 | 10393 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 36582 | 0.070 |
Why?
|
| Treatment Outcome | 4 | 2025 | 65295 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 6513 | 0.070 |
Why?
|
| Recurrence | 1 | 2018 | 8504 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2021 | 4049 | 0.060 |
Why?
|
| Transfection | 1 | 2013 | 5753 | 0.060 |
Why?
|
| Immunotherapy | 1 | 2022 | 4745 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 10748 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2021 | 6360 | 0.060 |
Why?
|
| Middle Aged | 6 | 2025 | 223233 | 0.060 |
Why?
|
| Adult | 5 | 2025 | 223317 | 0.050 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 5389 | 0.050 |
Why?
|
| Critical Care | 1 | 2015 | 2714 | 0.050 |
Why?
|
| Female | 7 | 2025 | 396660 | 0.050 |
Why?
|
| Mice, Transgenic | 1 | 2013 | 9551 | 0.050 |
Why?
|
| Quality of Life | 1 | 2022 | 13485 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2018 | 5716 | 0.040 |
Why?
|
| Mice | 3 | 2022 | 81912 | 0.040 |
Why?
|
| Male | 6 | 2025 | 364203 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 15424 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2022 | 4648 | 0.040 |
Why?
|
| Mutation | 1 | 2023 | 30211 | 0.040 |
Why?
|
| Immunity, Humoral | 1 | 2022 | 610 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2018 | 24299 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2021 | 13491 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 2022 | 1560 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 1105 | 0.030 |
Why?
|
| Immunologic Memory | 1 | 2022 | 1377 | 0.030 |
Why?
|
| Aged | 4 | 2025 | 171319 | 0.030 |
Why?
|
| Animals | 3 | 2022 | 168965 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2013 | 18330 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2022 | 2568 | 0.030 |
Why?
|
| Infant | 1 | 2015 | 36485 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2015 | 42606 | 0.020 |
Why?
|
| Risk Factors | 1 | 2019 | 74886 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2022 | 4405 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2018 | 4838 | 0.020 |
Why?
|
| Child | 1 | 2015 | 80771 | 0.020 |
Why?
|
| Adolescent | 1 | 2015 | 89046 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2023 | 9245 | 0.020 |
Why?
|
| Graft vs Host Disease | 1 | 2018 | 3049 | 0.020 |
Why?
|
| Sex Factors | 1 | 2018 | 10622 | 0.010 |
Why?
|
| Age Factors | 1 | 2018 | 18401 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2018 | 13048 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2025 | 59548 | 0.010 |
Why?
|
| Incidence | 1 | 2018 | 21526 | 0.010 |
Why?
|